This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Albanese, A., et al. (2001). “Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease.” 16(2): 197-201.AlbaneseA. (2001). “Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease.”16(2): 197-201.Search in Google Scholar
Bhidayasiri, R., et al. (2015). “Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.” 38(3): 89-103.BhidayasiriR. (2015). “Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.”38(3): 89-103.Search in Google Scholar
Bhidayasiri, R., et al. (2016). “Practical management of adverse events related to apomorphine therapy.” Parkinsonism Relat Disord 33 Suppl 1: S42-S48.BhidayasiriR. (2016). “Practical management of adverse events related to apomorphine therapy.”Parkinsonism Relat Disord33Suppl 1: S42-S48.Search in Google Scholar
Brown, W., et al. (1999). FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology, 53(6), 1212-1212.BrownW. (1999). FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology, 53(6), 1212-1212.Search in Google Scholar
Clarke, C., et al. (2000). “Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease.” 69(5): 590-594.ClarkeC. (2000). “Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease.”69(5): 590-594.Search in Google Scholar
Colosimo, C., Martínez‐Martín, P., Fabbrini, G., Hauser, R. A., Merello, M., Miyasaki, J., ... & Schrag, A. (2010). “Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations.” Movement Disorders, 25(9): 1131-1142.ColosimoC.Martínez-MartínP.FabbriniG.HauserR. A.MerelloM.MiyasakiJ.SchragA. (2010). “Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations.”Movement Disorders, 25(9):1131-1142.Search in Google Scholar
Colzi, A., et al. (1998). “Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease.” 64(5): 573-576.ColziA. (1998). “Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease.”64(5): 573-576.Search in Google Scholar
Deleu, D., et al. (2004). “Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease.” 21(11): 687-709.DeleuD. (2004). “Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease.”21(11): 687-709.Search in Google Scholar
Factor, S. A. J. N. (2004). “Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease.” 62(6 suppl 4): S12-S17.FactorS. A. J. N. (2004). “Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease.”62(6suppl 4): S12-S17.Search in Google Scholar
Frankel, J., et al. (1990). “Subcutaneous apomorphine in the treatment of Parkinson’s disease.” 53(2): 96-101.FrankelJ. (1990). “Subcutaneous apomorphine in the treatment of Parkinson’s disease.”53(2): 96-101.Search in Google Scholar
Hauser, R. A., et al. (2004). “Parkinson’s disease home diary: further validation and implications for clinical trials.” 19(12): 1409-1413.HauserR. A. (2004). “Parkinson’s disease home diary: further validation and implications for clinical trials.”19(12): 1409-1413.Search in Google Scholar
Isaacson, S., et al. (2016). “Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease.” 4(1): 78-83.IsaacsonS. (2016). “Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease.”4(1): 78-83.Search in Google Scholar
Jenner, P. and R. Katzenschlager (2016). “Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease.” Parkinsonism Relat Disord 33 Suppl 1: S13-S21.JennerP.KatzenschlagerR.(2016). “Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease.”Parkinsonism Relat Disord33Suppl 1: S13-S21.Search in Google Scholar
Katzenschlager, R., et al. (2018). “Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multi-centre, double-blind, randomised, placebo-controlled trial.” 17(9): 749-759.KatzenschlagerR. (2018). “Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multi-centre, double-blind, randomised, placebo-controlled trial.”17(9): 749-759.Search in Google Scholar
Mitchell, A. J. (2013). The Mini-Mental State Examination (MMSE): an update on its diagnostic validity for cognitive disorders. Cognitive screening instruments, Springer: 15-46.MitchellA. J. (2013). The Mini-Mental State Examination (MMSE): an update on its diagnostic validity for cognitive disorders. Cognitive screening instruments, Springer: 15-46.Search in Google Scholar
Muguet, D., et al. (1995). “Apomorphine in patients with Parkinson’s disease.” 49(4): 197-209.MuguetD. (1995). “Apomorphine in patients with Parkinson’s disease.”49(4): 197-209.Search in Google Scholar
NICE (2017). “Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care.”NICE (2017). “Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care.”Search in Google Scholar
Ondo, W. G., et al. (2012). “Apomorphine injections: predictors of initial common adverse events and long term tolerability.” Parkinsonism Relat Disord 18(5): 619-622.OndoW. G. (2012). “Apomorphine injections: predictors of initial common adverse events and long term tolerability.”Parkinsonism Relat Disord18(5): 619-622.Search in Google Scholar
Ostergaard, L., et al. (1995). “Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study.” 58(6): 681-687.OstergaardL. (1995). “Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study.”58(6): 681-687.Search in Google Scholar
Pahwa, R., et al. (2007). “Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.” 258(1-2): 137-143.PahwaR. (2007). “Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.”258(1-2): 137-143.Search in Google Scholar
Papapetropoulos, Spyridon. (2011). Patient Diaries As a Clinical Endpoint in Parkinson’s Disease Clinical Trials. CNS neuroscience & therapeutics. 18. 380-7. 10.1111/j.1755-5949.2011.00253.x.PapapetropoulosSpyridon. (2011). Patient Diaries As a Clinical Endpoint in Parkinson’s Disease Clinical Trials. CNS neuroscience & therapeutics. 18. 380-7. 10.1111/j.1755-5949.2011.00253.x.Open DOISearch in Google Scholar
Perez-Lloret, S. and O. J. C. d. Rascol (2010). “Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease.” 24(11): 941-968.Perez-LloretS.RascolO. J. C. d. (2010). “Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease.”24(11): 941-968.Search in Google Scholar
Pfeiffer, R. F., et al. (2007). “Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease.” Parkinsonism Relat Disord 13(2): 93-100.PfeifferR. F. (2007). “Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease.”Parkinsonism Relat Disord13(2): 93-100.Search in Google Scholar
Pietz, K., et al. (1998). “Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up.” 65(5): 709-716.PietzK. (1998). “Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up.”65(5): 709-716.Search in Google Scholar
Price, J., et al. (2016). “A case series of rapid titration of subcutaneous apomorphine in Parkinson’s disease.” 12(2): 70-74.PriceJ. (2016). “A case series of rapid titration of subcutaneous apomorphine in Parkinson’s disease.”12(2): 70-74.Search in Google Scholar
Sesar, Á., et al. (2017). “Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients.” 264(5): 946-954.SesarÁ. (2017). “Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients.”264(5): 946-954.Search in Google Scholar
Setter, S. M. J. N. c. (2008). “Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease.” 26(3): 45-63.SetterS. M. J. N. c. (2008). “Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease.”26(3): 45-63.Search in Google Scholar
Tomlinson, C. L., et al. (2010). “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease.” 25(15): 2649-2653.TomlinsonC. L. (2010). “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease.”25(15): 2649-2653.Search in Google Scholar
Trenkwalder, C., et al. (2015). “Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease –clinical practice recommendations.” 21(9): 1023-1030.TrenkwalderC. (2015). “Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease –clinical practice recommendations.”21(9): 1023-1030.Search in Google Scholar
van Laar, T. and R. Borgemeester (2016). “The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine.” Parkinsonism Relat Disord 33 Suppl 1: S22-S27.van LaarT.BorgemeesterR. (2016). “The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine.”Parkinsonism Relat Disord33Suppl 1: S22-S27.Search in Google Scholar